Stacy L Moulder
Overview
Explore the profile of Stacy L Moulder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2969
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinkenbaugh A, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones S, et al.
bioRxiv
. 2024 Dec;
PMID: 39651299
Triple negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity...
2.
Yam C, Patel M, Hill H, Sun R, Bassett Jr R, Kong E, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2823-2834.
PMID: 39356138
Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the...
3.
Chen J, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, et al.
BMC Cancer
. 2024 Aug;
24(1):1016.
PMID: 39148033
Background: Triple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) could predict response...
4.
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, et al.
Cell Rep Med
. 2024 Jun;
5(6):101595.
PMID: 38838676
Luminal androgen receptor (LAR)-enriched triple-negative breast cancer (TNBC) is a distinct subtype. The efficacy of AR inhibitors and the relevant biomarkers in neoadjuvant therapy (NAT) are yet to be determined....
5.
Iwase T, Cohen E, Gao H, Alexander A, Kai M, Chiv V, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2424-2432.
PMID: 38629963
Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy...
6.
Basho R, Zhao L, White J, Huo L, Bassett R, Mittendorf E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300124.
PMID: 38484209
Purpose: The PI3K pathway is frequently altered in triple-negative breast cancer (TNBC). Limited cell line and human data suggest that TNBC tumors characterized as mesenchymal (M) and luminal androgen receptor...
7.
Yam C, Mittendorf E, Garber H, Sun R, Damodaran S, Murthy R, et al.
Breast Cancer Res Treat
. 2023 Apr;
199(3):457-469.
PMID: 37061619
Purpose: Neoadjuvant anti-PD-(L)1 therapy improves the pathological complete response (pCR) rate in unselected triple-negative breast cancer (TNBC). Given the potential for long-term morbidity from immune-related adverse events (irAEs), optimizing the...
8.
Echeverria G, Cai S, Tu Y, Shao J, Powell E, Redwood A, et al.
NPJ Breast Cancer
. 2023 Jan;
9(1):2.
PMID: 36627285
Patient-derived xenograft (PDX) models of breast cancer are an effective discovery platform and tool for preclinical pharmacologic testing and biomarker identification. We established orthotopic PDX models of triple negative breast...
9.
Mitri Z, Abuhadra N, Goodyear S, Hobbs E, Kaempf A, Thompson A, et al.
NPJ Precis Oncol
. 2022 Sep;
6(1):64.
PMID: 36085319
Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity to enhance clinical management. We applied an Evolutionary Action Score to functionally characterize TP53 mutations...
10.
Liu X, Ge Z, Yang F, Contreras A, Lee S, White J, et al.
NPJ Breast Cancer
. 2022 May;
8(1):64.
PMID: 35538088
Germline mutations in BRCA1 or BRCA2 exist in ~2-7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported...